Related Experiment Video
Updated: Apr 25, 2026
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
Outcomes with cytoreductive surgery and HIPEC for peritoneal metastasis
Shuja Ahmed1, John H Stewart, Perry Shen
1Surgical Oncology Service, Department of General Surgery, Wake Forest Baptist Medical Center, Winston Salem, North Carolina.
Abstract:
Peritoneal metastasis (PM) has traditionally been approached with therapeutic nihilism. The evolution of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) over the last two decades, however, has caused a paradigm shift in treatment for PM. This modality is rapidly gaining acceptance as standard of care for PM from various cancers. This article reviews the current literature regarding the use of CRS/HIPEC for PM from the most common intra-abdominal malignancies.
